Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Ghanizadeh,A, Rezaee,Z, Dehbozorgi,S, Berk,M and Akhondzadeh,S 2014, Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial., Psychiatry Research, vol. 219, no. 3, pp. 431-435, doi: 10.1016/j.psychres.2014.06.039. Attached Files Name Description MIMEType Size Downloads SYMPLECTIC-LICENCE DRO_Licence_Agreement.txt text/plain 1.48KB 12 Title Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Author(s) Ghanizadeh,A Rezaee,Z Dehbozorgi,S Berk,M orcid.org/0000-0002-5554-6946 Akhondzadeh,S Journal name Psychiatry Research Volume number 219 Issue number 3 Start page 431 End page 435 Publisher Elsevier Place of publication Amsterdam, The Netherlands Publication date 2014-11-30 ISSN 1872-7123 Keyword(s) Inflammation Lovastatin Oxidative stress Risperidone Schizophrenia Statins Science & Technology Life Sciences & Biomedicine Psychiatry LIPID-LOWERING MEDICATIONS MAJOR DEPRESSIVE DISORDER N-ACETYL CYSTEINE ADD-ON THERAPY BIPOLAR DISORDER STATIN USE METAANALYSIS ANTIPSYCHOTICS ACTIVATION CELECOXIB Summary While statins target many of the pathways to neuroprogression in schizophrenia, the safety and efficacy of statins for treating schizophrenia has never been examined. This is an 8-week randomized double blind controlled clinical trial examining the efficacy and safety of adjunctive lovastatin (20 mg/day) treatment or placebo for people with schizophrenia. The baseline characteristics of the two groups were not different. Endpoint changes in Positive and Negative Syndrome Scale (PANSS) total and subscale scores did not differ between the two groups. However there was a significant difference between the doses of risperidone used in the two groups. The mean dose in the lovastatin and placebo groups were 4.8(1.8) and 3.4(1.4) mg/day, respectively (P<.03). No serious adverse events were reported. Slowness of movements, muscle rigidity, increased appetite, and decreased energy were the most common adverse effects, and these rates did not differ between the two groups. This study failed to demonstrate a benefit of lovastatin on symptoms of schizophrenia. This combination was well tolerated. However, a higher dosage of risperidone was used for treating the disorder in those taking concomitant lovastatin compared to placebo. Language eng DOI 10.1016/j.psychres.2014.06.039 Field of Research 110999 Neurosciences not elsewhere classified Socio Economic Objective 920410 Mental Health HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Persistent URL http://hdl.handle.net/10536/DRO/DU:30067177 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges   Author URL Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Tue, 28 Oct 2014, 13:29:02 EST Tue, 28 Oct 2014, 13:30:03 EST Thu, 30 Oct 2014, 14:10:50 EST Thu, 30 Oct 2014, 14:13:21 EST Thu, 30 Oct 2014, 14:18:29 EST Thu, 30 Oct 2014, 14:31:13 EST Thu, 30 Oct 2014, 14:32:26 EST Thu, 30 Oct 2014, 14:33:52 EST Thu, 06 Nov 2014, 13:43:44 EST Thu, 06 Nov 2014, 13:49:27 EST Tue, 11 Nov 2014, 08:25:28 EST Thu, 13 Nov 2014, 09:12:34 EST Mon, 12 Oct 2015, 15:37:07 EST Filtered Full Citation counts:   Cited 12 times in TR Web of Science Cited 15 times in Scopus Search Google Scholar Access Statistics: 547 Abstract Views, 14 File Downloads  -  Detailed Statistics Created: Thu, 30 Oct 2014, 14:33:52 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.